Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital

Rhea-AI Summary

Outlook Therapeutics (Nasdaq: OTLK) announced that Lawrence Kenyon, its President, CEO, and CFO, will participate in the BIO Investor Forum Digital from October 13-15, 2020. The firm aims to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg (ONS-5010) for retinal diseases such as wet AMD, DME, and BRVO. The corporate presentation will be available on-demand during the conference. Interested investors can schedule virtual one-on-one meetings via the conference portal.

MONMOUTH JUNCTION, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence Kenyon, President, CEO and CFO of Outlook Therapeutics, will participate at the BIO Investor Forum Digital taking place on October 13-15, 2020.

The Outlook Therapeutics corporate presentation will be available on-demand during the conference to those registered to attend. Additionally, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend. Interested parties can request a meeting through the conference portal. For additional information about the conference, please visit the conference website.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:

Media Inquiries:
Jessica Morris
Account Executive
LaVoie Health Science
T: 857.701.9731
jmorris@lavoiehealthscience.com

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247 
OTLK@jtcir.com

FAQ

What is the purpose of Outlook Therapeutics' participation in the BIO Investor Forum Digital?

Outlook Therapeutics aims to present its clinical developments and seek investor engagement during the BIO Investor Forum Digital from October 13-15, 2020.

What is ONS-5010 and its significance for Outlook Therapeutics?

ONS-5010 is the first FDA-approved ophthalmic formulation of bevacizumab-vikg that Outlook Therapeutics is developing for treating retinal diseases.

When will the corporate presentation of Outlook Therapeutics be available?

The corporate presentation will be available on-demand during the BIO Investor Forum Digital from October 13-15, 2020.

How can investors schedule meetings with Outlook Therapeutics during the conference?

Interested investors can schedule virtual one-on-one meetings through the conference portal.

What retinal diseases does Outlook Therapeutics target with ONS-5010?

Outlook Therapeutics targets major retinal diseases, including wet AMD, DME, and BRVO with ONS-5010.